Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …

Muscle weakness and fatigue are the hallmarks of autoimmune neuromuscular junction
disorders. Although a plethora of immunosuppressive treatments exist, no cure is available …

Myasthenia gravis (MG) is the most extensively studied antibody-mediated disease in
humans. Substantial progress has been made in the treatment of MG in the last century …

Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy
centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and …

The thymus prevents autoimmune diseases through mechanisms that operate in the cortex
and medulla, comprising positive and negative selection and the generation of regulatory T …

Introduction Several patients with myasthenia gravis (MG) do not adequately respond to
available drugs or exhibit poor tolerance, necessitating the need for new therapies. Areas …

Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital
myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare …

Myasthenia gravis (MG) is a prototypical autoantibody mediated disease. The
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …

When the diagnosis of myasthenia gravis (MG) has been secured, the aim of management
should be prompt symptom control and the induction of remission or minimal manifestations …

CBAs can lead to a significant reduction of seronegative patients, improving myasthenia
gravis diagnostic process. New biological drugs offer innovative approaches to treat …